Objective
Cholera remains a severe diarrhoeal disease that can kill within hours if untreated. Despite being preventable and treatable, cholera continues to cause major public health crises, with over 730,000 cases and 5,000 deaths reported globally in 2024, the majority in sub-Saharan Africa. Climate change, extreme weather events, fragile healthcare systems and inadequate WASH infrastructure exacerbate the persistence of cholera and undermine existing control strategies. Although oral cholera vaccines have proven effective, global shortages and waning immunity highlight the urgent need for complementary interventions.
HUNADIA addresses this gap by developing and clinically validating a novel oral antidiarrhoeal treatment (VR-AD-1005, “VR”) that directly neutralises cholera toxin-induced fluid loss, where rehydration and antibiotics fall short. Building on a successful Phase II trial in Bangladesh, which demonstrated an eightfold reduction in stool volume and halved hospitalisation times, HUNADIA will conduct a large-scale, adaptive Phase IIb/III, placebo-controlled trial across 7 high-burden SSA countries. The trial will generate robust evidence on safety, efficacy and clinical utility, including in vulnerable populations.
Our multidisciplinary consortium unites 11 partners from Africa, Europe and Asia, spanning drug discovery, GMP manufacturing, late-stage clinical research, health economics and policy translation. By strengthening African clinical trial capacity, engaging with all stakeholder groups and integrating climate-health data, HUNADIA is uniquely positioned to deliver a scientifically sound, clinically effective, cost-efficient and socially accepted solution. By reducing cholera morbidity and mortality, alleviating the burden on health systems and enabling rapid outbreak response, HUNADIA will contribute directly to epidemic preparedness, affordable access to innovations, and the Global Task Force on Cholera Control’s 2030 elimination roadmap.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences public health
- social sciences sociology demography mortality
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- natural sciences earth and related environmental sciences atmospheric sciences climatology climatic changes
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.2.1 - Health
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-JU-GH-EDCTP3-2025-04-two-stage
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
30201 CARTAGENA
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.